Tiaramide--a new oral drug for the treatment of asthma.

Abstract

1 TIaramide, an anti-inflammatory drug, inhibits the action of mediators released from mast cells and has direct smooth muscle relaxant properties. It may therefore have a beneficial effect in asthma. 2 A double-blind crossover trial comparing the bronchodilator activity of tiaramide and placebo over 16 days was undertaken in 13 patients with asthma. 3 Peak expiratory flow rate (PEFR) was recorded on three separate occasions every day and frequency of salbutamol aerosol usage was noted on a diary card. 4 During treatment with tiaramide the mean mid-morning PEFR (362 1/min) was higher than mean PEFR on placebo (328) (P less than 0.001) as was the evening PEFR (378) compared with placebo (388) (P less than 0.001). 5 There was a significant reduction in daily use of the salbutamol inhaler whilst on tiaramide (1.8) compared with placebo (2.3) (P less than 0.05). 6. Tiaramide may be a useful addition to existing prophylactic treatment for asthma.

• Authors: K E Berkin, J W Kerr
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 14 Issue 4 Pg. 505-8 (Oct 1982) ISSN: 0306-5251 [Print] England
• PMID: 7138736 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Benzothiazoles
• Bronchodilator Agents
• Piperazines
• tiaramide

Topics

• Adolescent
• Adult
• Asthma (drug therapy, physiopathology)
• Benzothiazoles
• Bronchodilator Agents (therapeutic use)
• Female
• Forced Expiratory Volume
• Humans
• Male
• Middle Aged
• Peak Expiratory Flow Rate
• Piperazines (therapeutic use)